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Acute and chronic graft-versus-host disease (GVHD) remain major obstacles for successful allogeneic he-
matopoietic cell transplantation. Extracorporeal photopheresis (ECP) modulates immune cells, such as
alloreactive T cells and dendritic cells, and improves GVHD target organ function(s) in steroid-refractory
GVHD patients. We performed a systematic review to evaluate the totality of evidence regarding the efﬁ-
cacy of ECP for treatment of acute and chronic steroid-refractory or steroid-dependent GVHD. Nine studies,
including 1 randomized controlled trial, met inclusion criteria, with a total of 323 subjects. In pooled analyses,
overall response rates (ORR) were .69 (95% conﬁdence interval [CI], .34 to .95) and .64 (95% CI, .47 to .79) for
acute and chronic GVHD, respectively. In acute GVHD organ-speciﬁc responses, ECP resulted in the highest
ORR for cutaneous, with .84 (95% CI, .75 to .92), followed by gastrointestinal with .65 (95% CI, .52 to .78).
Similar response rates were seen in chronic GVHD involving the skin and gastrointestinal tract. Conversely,
ORR for chronic GVHD involving the lungs was only .15 (95% CI, 0 to .5). In chronic GVHD, grades 3 to 4
adverse events were reported at .38 (95% CI, .06 to .78). ECP-related mortality rates were extremely low. Rates
of immunosuppression discontinuation were .55 (95% CI, .40 to .70) and .23 (95% CI, .07 to .44) for acute and
chronic GVHD, respectively. In summary, albeit limited by numbers of available studies, pooled analyses of
prospective studies demonstrate encouraging responses after ECP treatment in acute and chronic GVHD after
failing corticosteroids. Further research efforts are needed to improve organ-speciﬁc responses.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT)
remains the only known curative therapeutic modality for
various hematologic malignancies and blood disorders [1-7].
The efﬁcacy of allo-HCT is limited, however, by development
of acute and/or chronic graft-versus-host disease (GVHD),
which is associated with substantial morbidity and contrib-
utes signiﬁcantly to the nonrelapse mortality associated with
hematopoietic cell allografting [8-11]. Higher incidences of
acute and chronic GVHD are observed after use of unrelateddgments on page 1684.
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14.05.017donors, especially with HLA mismatching, as well as use of
granulocyte colonyestimulating factoremobilized periph-
eral blood stem cells, among other reasons [12-15].
Therapy for acute and/or chronic GVHD relies primarily
on administration of corticosteroids, namely prednisone at a
starting dose of 1 to 2mg/kg [16]. Unfortunately, a signiﬁcant
number of patients (approximately 40% to 50%) do not
respond or are unable to tolerate tapering of prednisone dose
below .5 mg/kg/day [10,17]. In such cases, a second-line
therapy is generally added [18-20]; however, at the present
time, no particular immune-suppressive agent or therapy is
considered a standard option in this setting [21].
There is a prevailing consensus among transplantation
physicians to offer patients with steroid-refractory acute or
chronic GVHD participation in clinical trials whenever
possible. In cases of ineligibility or unavailability of such
trials, the choice of second-line therapy is largely based onTransplantation.
I. Abu-Dalle et al. / Biol Blood Marrow Transplant 20 (2014) 1677e16861678physician preference, familiarity with a particular treatment
option, or institutional standard operating procedures.
Extracorporeal photopheresis (ECP), also known as
extracorporeal photochemotherapy, involves ex vivo expo-
sure of mononuclear cells obtained by apheresis to a pho-
tosensitizing agent, 8-methoxypsoralen, and ultraviolet A
(UVA) light, followed by reinfusion of the treated cells to the
patient [22-30]. The precise mechanism of ECP in the setting
of acute and/or chronic GVHD is not clearly understood.
Various possible mechanisms to explain GVHD (acute or
chronic) responses after ECP have been described, including
normalization of CD4þ/CD8þ lymphocyte populations and a
decrease in circulating dendritic cells (CD80þ and CD123þ),
among others [31-33].
With the exception of 1 randomized controlled trial (RCT)
[30], published data evaluating the efﬁcacy of ECP for the
treatment of steroid-refractory, steroid-dependent, or
steroid-intolerant acute and/or chronic GVHD are limited to
nonrandomized single-institution prospective trials, retro-
spective data, or small case series [22-29,34]. These studies
describe varying, and at times conﬂicting, results regarding
the overall and organ-speciﬁc responses. Accordingly, we
performed a systematic review to evaluate the totality of
evidence regarding the efﬁcacy or lack thereof of ECP for the
treatment of steroid-refractory or steroid-dependent acute
or chronic GVHD.METHODS
Literature Search
A comprehensive literature search was undertaken using Medline/
PubMed and Cochrane Collaboration for prospective studies published from
inception until March 5, 2013. The search was conducted using the search
strategy described in Appendix 1. Relevant references within each reviewed
manuscript or review were scanned to identify other potentially relevant
(and eligible) studies. No search limits were applied.Literature search of PubMed and 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRIS
versus-host disease; RCT, randomized controlled trial.Inclusion Criteria
Only prospective interventional trials (RCT or observational) evaluating
the efﬁcacy of ECP for treatment of steroid-refractory or steroid-dependent
acute or chronic GVHD were eligible. Moreover, a minimum number of 5
subjects were required, without any age restriction. Single case reports and
studies addressing ECP as preventive therapy were excluded in this analysis.
Study Selection, Quality Assessment, and Data Extraction
All retrieved articles were scanned for relevance initially on title and
abstract followed by full text readings by 2 independent authors (I.A.-D.
and A.A.) in consultation with other authors (T.R. and M.A.K.-D.). Dis-
agreements were resolved by consensus. Two independent authors (I.A.-D.
and A.A.) extracted data from all studies using a standardized data
extraction form. Data were collected on patient characteristics, clinical
outcomes (beneﬁts and harms), adverse events, andmethodological quality
of all included studies. A third author (T.R.) veriﬁed data before analysis.
Methodological quality of included randomized controlled trials was
assessed using the Cochrane tool for assessment of bias [35] and for non-
comparative cohort studies using the Newcastle-Ottawa scale modiﬁed for
single-arm cohort [36].
Data Analysis and Statistical Methods
Proportion was calculated for each outcome and trials, which had
similar deﬁnitions in terms of study design, patients, intervention, control;
and outcomes were summarized and pooled [37]. Methods by Stuart et al.
[38] were used to transform the proportions into a quantity suitable for
random-effects pooling. The pooled proportion was then calculated as a
back-transform of the weighted mean of transformed proportions, using the
random-effects model [38]. Heterogeneity was tested using the I2 test [38].
An I2 above 30% was considered moderate heterogeneity and above 60% was
considered high heterogeneity. Meta-analyses were performed using Stats-
Direct version 2.7.8 (Altrincham, UK). This systematic review is reported
according to the Preferred Reporting Items for Systematic Reviews and
Meta-analyses guidelines [39].
RESULTS
Identiﬁcation of Eligible Studies
The initial search yielded 378 references, of which 330
were excluded for reasons described in Figure 1. A full-text
review of the 48 remaining manuscripts excluded ancluded (N=330)
4 - Not a clinical study
 - Not involving ECP
 - Did not enroll patients with steroid 
fractory GVHD
 - Other
xcluded (N=39)
- Not a clinical study
- Not involving ECP
 - Duplicate publication of included studies
 - Retrospective
 - Less than 5 patients with steroid 
refractory/intolerant-GVHD
MA) ﬂow diagram. ECP indicates extracorporeal photopheresis; GVHD, graft-
Table 1
Characteristics of Single-Arm Included Studies
Study, yr Total
n
Patient Age,
median
(range), yr
Primary Disease Donor Source GVHD Type Organ(s) Criteria for
ECP Initiation
Immunotherapy before ECP ECP Treatment
Smith et al., 1998 24 29 (5.7-53) CML, acute leukemia,
aplastic anemia, MDS
MRD ¼ 17
Mismatched
related donor ¼ 1
MUD ¼ 6
Acute ¼ 6
Chronic ¼ 18
Various Steroid refractory
GVHD*
CSA, ATG, PUVA ECP system:
Therakos Uvar XTS
Regimen:
aGVHD: received 2-3 procedures/
week
cGVHD: initially received 2
consecutive procedures every
3 weeks; then intensiﬁed to
2-3/week
Salvaneschi
et al., 2001
23 10.3 (5.4-18.1) Leukemia, thalassemia
major, severe aplastic
anemia
MRD ¼ 12
Mismatched
related donor ¼ 1
MUD ¼ 10
Acute grade
III-IV ¼ 9
Chronic
limited ¼ 2
Extensive ¼ 12
Various Steroid refractory
GVHD*
CSA, TAC, THAL, PUVA,
azathioprine
ECP system:
Cobe Spectra
Regimen:
aGVHD: 3 times/week,
responding patients treated
with 2 consecutive days at
2-week intervals  3 months
cGVHD: 2 consecutive days
at 2-week intervals x 3 months
Seaton et al.,
2003
28 34 (18-51) AML, ALL, CML, MM MRD ¼ 19
MUD ¼ 9
Chronic
limited ¼ 1
Extensive ¼ 27
Various Steroid refractory
GVHD*
MMF, MTX, CSA, TAC, CTX,
PUVA, azathioprine
ECP system:
Therakos Uvar XTS
Regimen:
cGVHD: 2 consecutive days every
2 weeks  4 months then monthly
Foss et al., 2005 25 42 (18-59) AML, ALL, CLL, CML, NHL MRD ¼ 17
MUD ¼ 8
Chronic
extensive ¼ 25
Various Steroid refractory
or steroid intolerant*
MMF, CSA, TAC,
pentostatin, plaquenil
ECP system:
Therakos Uvar XTS
Regimen:
cGVHD: 2 consecutive days every
2 weeks or once per week
Garban et al.,
2005
27 aGVHD:
40 (23-63)
cGVHD:
45 (14-62)
AML, acute leukemia,
CML, MDS, MM, Fanconi’s
anemia, solid tumor
MRD ¼ 21
MUD ¼ 6
Acute grade
III-IV ¼ 12
Chronic
extensive ¼ 15
Various Steroid refractory
or steroid resistant*
MMF, MTX, CSA, TAC,
chlorambucil
ECP system:
Cobe Spectra
Regimen:
6 courses within 3 weeks, after
3 weeks treatment stopped if
complete or no response, and
continue 1 course per week if
partial response
Greinix et al.,
2006
59 40 (21-60) AML, ALL, CML, other Not reported Acute grade
II-IV ¼ 59
Various Steroid refractory
or dependent GVHD
CSA ECP system:
Therakos Uvar XTS
Regimen:
aGVHD: 2 consecutive days every
1 to 2 weeks until improvement.
In ﬁrst 21 patients, reduces to every
2 to 4 weeks until maximum
response
Kanold et al.,
2007
27 14 (4-18) AML, ALL, CML, severe
aplastic anemia, NHL,
other
Not reported Acute grade
II-IV ¼ 12
Chronic
limited ¼ 3
extensive ¼ 12
Various Steroid refractory or
steroid intolerant
GVHD*
MMF, pentostatin,
inolimomab, RTX, TAC,
THAL, azathioprin,
inﬂiximab, monoclonal Ab
ECP system:
Cobe Spectra
Regimen:
As per Andreu et al. [40]
(continued on next page)
I.A
bu-D
alle
et
al./
Biol
Blood
M
arrow
Transplant
20
(2014)
1677
e
1686
1679
Ta
b
le
1
(c
on
ti
nu
ed
)
St
u
d
y,
yr
To
ta
l
n
Pa
ti
en
t
A
ge
,
m
ed
ia
n
(r
an
ge
),
yr
Pr
im
ar
y
D
is
ea
se
D
on
or
So
u
rc
e
G
V
H
D
Ty
p
e
O
rg
an
(s
)
C
ri
te
ri
a
fo
r
EC
P
In
it
ia
ti
on
Im
m
u
n
ot
h
er
ap
y
be
fo
re
EC
P
EC
P
Tr
ea
tm
en
t
C
al
or
e
et
al
.,
20
08
15
9.
6
(1
.4
-1
8.
1)
A
M
L,
A
LL
,N
H
L
M
R
D
¼
9
M
is
m
at
ch
ed
¼
6
A
cu
te
gr
ad
e
II
-I
V
¼
15
V
ar
io
u
s
St
er
oi
d
re
fr
ac
to
ry
or
d
ep
en
d
en
t
G
V
H
D
or
vi
ra
l
re
ac
ti
va
ti
on
(E
B
V
or
C
M
V
)y
N
ot
re
p
or
te
d
EC
P
sy
st
em
:
C
ob
e
Sp
ec
tr
a
R
eg
im
en
:
aG
V
H
D
:
2
co
n
se
cu
ti
ve
d
ay
s
ev
er
y
w
ee
k
fo
r
th
e
ﬁ
rs
t
m
on
th
,e
ve
ry
2
w
ee
ks
fo
r
th
e
se
co
n
d
an
d
th
ir
d
m
on
th
th
en
m
on
th
ly
fo
r
at
le
as
t
3
m
on
th
s
Fl
ow
er
s
et
al
.,
20
08
95
z
41
(1
6-
67
)x
A
M
L,
A
LL
,C
M
L,
N
H
L,
ot
h
er
s
R
el
at
ed
¼
31
U
n
re
la
te
d
¼
17
C
h
ro
n
ic
G
V
H
D
lim
it
ed
¼
3
ex
te
n
si
ve
¼
45
V
ar
io
u
s
St
er
oi
d
re
fr
ac
to
ry
or
d
ep
en
d
en
t
or
in
to
le
ra
n
t
M
M
F,
C
SA
,T
A
C
EC
P
sy
st
em
:
Th
er
ak
os
U
va
r
R
eg
im
en
:
3
ti
m
es
d
u
ri
n
g
w
ee
k
1,
th
en
tw
ic
e
w
ee
kl
y
(w
ee
ks
2-
12
).
If
re
sp
on
se
,c
on
ti
n
u
e
2
tr
ea
tm
en
ts
ev
er
y
4
w
ee
ks
ti
ll
w
ee
k
24
C
M
L
in
d
ic
at
es
ch
ro
n
ic
m
ye
lo
id
le
u
ke
m
ia
;
M
D
S,
m
ye
lo
d
ys
p
la
st
ic
sy
n
d
ro
m
e;
M
R
D
,m
at
ch
ed
re
la
te
d
d
on
or
s;
M
U
D
,m
at
ch
ed
u
n
re
la
te
d
d
on
or
s;
C
SA
,c
yc
lo
sp
or
in
e
A
;
A
TG
,a
n
ti
th
ym
oc
yt
e
gl
ob
u
lin
;
PU
V
A
,p
so
ra
le
n
þ
U
V
A
;
aG
V
H
D
,
ac
u
te
gr
af
t-
ve
rs
u
s-
h
os
t
d
is
ea
se
;
cG
V
H
D
,c
h
ro
n
ic
gr
af
t-
ve
rs
u
s-
h
os
t
d
is
ea
se
;
TA
C
,t
ac
ro
lim
u
s;
TH
A
L,
th
al
id
om
id
e;
A
M
L,
ac
u
te
m
ye
lo
id
le
u
ke
m
ia
;
A
LL
,a
cu
te
ly
m
p
h
oi
d
le
u
ke
m
ia
;
M
M
,m
u
lt
ip
le
m
ye
lo
m
a;
M
M
F,
m
yc
op
h
en
ol
at
e
m
of
et
il;
M
TX
,m
et
h
ot
re
xa
te
;
C
TX
,c
yc
lo
p
h
os
p
h
am
id
e;
C
LL
,c
h
ro
n
ic
ly
m
p
h
oc
yt
ic
le
u
ke
m
ia
;
N
H
L,
n
on
-H
od
gk
in
ly
m
p
h
om
a;
R
TX
,r
it
u
xi
m
ab
;
EB
V
,E
p
st
ei
n
-B
ar
r
vi
ru
s;
C
M
V
,c
yt
om
eg
al
ov
ir
u
s.
*
M
ay
h
av
e
re
ce
iv
ed
ot
h
er
th
er
ap
ie
s
be
si
d
es
st
er
oi
d
s
be
fo
re
in
it
ia
ti
on
of
EC
P.
y
St
u
d
y
al
so
re
p
or
ts
on
16
ac
u
te
G
V
H
D
p
at
ie
n
ts
w
it
h
go
od
re
sp
on
se
to
st
er
oi
d
s
n
ot
in
cl
u
d
ed
in
th
is
an
al
ys
is
.
z
Fo
rt
y-
ei
gh
t
p
at
ie
n
ts
re
ce
iv
ed
st
an
d
ar
d
th
er
ap
y
p
lu
s
EC
P
an
d
47
re
ce
iv
ed
st
an
d
ar
d
th
er
ap
y
al
on
e
x
Pa
ti
en
ts
w
h
o
re
ce
iv
ed
EC
P.
I. Abu-Dalle et al. / Biol Blood Marrow Transplant 20 (2014) 1677e16861680additional 39 references for various reasons illustrated in
Figure 1. Nine studies (RCT ¼ 1, non-RCT ¼ 8), enrolling a
total of 323 subjects, were included in this systematic review.
Randomized controlled trial
One RCT enrolling 47 patients (25 steroid-dependent, 5
steroid-refractory, and 17 steroid-intolerant patients) on
standard therapy and 48 patients (28 steroid-dependent, 7
steroid-refractory, and 13 steroid-intolerant patients) on an
ECP treatment arm were identiﬁed [30]. This study showed
that ECP was well tolerated and resulted in a higher pro-
portion of patients with chronic GVHD to achieve 50%
reduction of corticosteroids (byweek 12 after ECP treatment)
and 25% decrease in total skin score (compared with
baseline) (8.3% versus 0%, P ¼ .04) [30]. Superiority of ECP
was also observed in various extracutaneous organs affected
with chronic GVHD, namely ocular (30% versus 7%, P ¼ .04)
and oral mucosa (53% versus 27%, P ¼ .06) [30]. The meth-
odological quality of this study was adequate (Appendix 2).
Observational studies
Eight observational studies enrolled a total of 228 pa-
tients. Six of the 8 studies (n ¼ 176) included subjects with
steroid-refractory or steroid-dependent acute or chronic
GVHD [22-24,26,27,29]. The remaining 2 studies (n ¼ 52)
included subjects with steroid-intolerant GVHD, in addition
to steroid-refractory or steroid-dependent cases [25,28]. One
study evaluated the role of ECP therapy as treatment of viral
reactivation, speciﬁcally cytomegalovirus (n ¼ 2 of 15) and
Epstein-Barr virus (n ¼ 4 of 15) in association with steroid-
refractory GVHD (n ¼ 15 of 15) [29]. ECP was used for
treatment of acute GVHD in 113 and for chronic GVHD in 115
subjects. Overall methodological quality of studies was
moderate (Appendix 2).OUTCOMES
Characteristics of the studies included in this analysis are
summarized in Table 1. Our analysis did not exclude patients
with steroid-intolerant GVHD because the post-ECP treat-
ment outcomes reported in pertinent studies [25,28] did not
discriminate outcomes for each speciﬁc indication (ie,
steroid-intolerant or steroid-refractory). Moreover, in 1
study, it was impossible to ascertain the precise number of
subjects with steroid-intolerant GVHD [25]. We analyzed
outcomes of ECP therapy based on beneﬁts (overall response
and organ-speciﬁc response) and harms (any grade 3 and 4
adverse events and ECP-relatedmortality) in patients treated
for acute or chronic GVHD. Whenever possible, data were
also analyzed based on organ-speciﬁc responses. We also
analyzed the ability to discontinue immunosuppresive
therapies after initiation of ECP.BENEFITS
Overall Response
For acute GVHD
Data on overall response rate (ORR) were extracted from 6
studies (54 patients) [22,23,26-29]. The pooled proportion of
ORR for ECP in various organs using the random effects was
.69 (95% CI, .34 to .95) (Figure 2A). There was high hetero-
geneity between studies (I2 ¼ 87%). Data on complete
response (CR) were extracted from 5 studies (101 patients)
[22,23,27-29]. The pooled proportion of CR in various organs
was .53 (95% CI, .31 to .74). There was high heterogeneity
between studies (I2 ¼ 76%).
Figure 2. Overall response after ECP in acute (A) and chronic (B) GVHD.
I. Abu-Dalle et al. / Biol Blood Marrow Transplant 20 (2014) 1677e1686 1681Responses based on acute GVHD organ speciﬁcity (cuta-
neous, gastrointestinal, and hepatic) were as follows: pooled
ORR for cutaneous in 5 studies (103 patients) was .84 (95% CI,
.75 to .92), gastrointestinal in 5 studies (45 patients) was .65
(95% CI, .52 to .78), and hepatic in 5 studies (38 patients) was
.55 (95% CI, .35 to .74) (Figure 3A-C). Overall heterogeneity
between studies was low: I2¼ 22%, 0%, and 27%, respectively.
For chronic GVHD
ORR data were extracted from 5 studies (87 patients)
[22,23,25,26,28]. The pooled proportion of ORR for ECP in
various organs using the random effects was .64 (95% CI, .47
to .79) (Figure 2B). There was high heterogeneity betweenFigure 3. Acute GVHD organ-speciﬁc response: cutaneous (A), gastrointesstudies (I2 ¼ 64%). Data on CR were extracted from 5 studies
(87 patients) [22,23,25,26,28]. The pooled proportion of CR
in various organs was .26 (95% CI, .05 to .55). There was high
heterogeneity between studies (I2 ¼ 88%).
Responses based on chronic GVHD organ speciﬁcity
(cutaneous, gastrointestinal, hepatic, oral mucosa, musculo-
skeletal, and pulmonary) were as follows: pooled ORR for
cutaneous in 4 studies (70 patients) was .71 (95% CI, .57 to
.84), gastrointestinal in 2 studies (9 patients) was .62 (95% CI,
.21 to .94), hepatic in 3 studies (45 patients) was .58 (95% CI,
.27 to .86), oral mucosa in 3 studies (32 patients) was .63
(95% CI, .43 to .81), musculoskeletal in 2 studies (9 patients)
was .45 (95% CI, .18 to .74), and pulmonary in 3 studies (12tinal (B), and hepatic (C). GVHD indicates graft-versus-host disease.
Figure 4. Chronic GVHD organ-speciﬁc response: cutaneous (A), gastrointestinal (B), hepatic (C), and oral mucosa (D).
I. Abu-Dalle et al. / Biol Blood Marrow Transplant 20 (2014) 1677e16861682patients) was .15 (95% CI, 0 to .50) (Figure 4A-D). Heteroge-
neity between studies was moderate for cutaneous
(I2 ¼ 39%), oral mucosa (I2 ¼ 34%), and pulmonary (I2 ¼ 45%)
GVHD and high for hepatic GVHD (I2 ¼ 77%). There
were too few studies for the outcomes of gastrointestinal
and musculoskeletal GVHD to compute measure of
heterogeneity.
HARMS
Any Grade Three or Four Adverse Events
For acute GVHD
None of the included studies reported data on any grade 3
or 4 adverse events among patients with acute GVHD.
For chronic GVHD
The pooled incidence of any grade 3 or 4 adverse events
from 2 studies (53 patients) was .38 (95% CI, .06 to .78)
[24,25]. There were too few studies to estimate heteroge-
neity between studies. Seaton et al. reported severe com-
plications in 5 of 28 subjects who received ECP for treatment
of chronic GVHD: renal failure/sepsis, n ¼ 1; acute respira-
tory distress syndrome of unknown cause, n ¼ 1; pneumo-
thorax/pleural effusion, n ¼ 1; ischemic heart disease, n ¼ 1;
and unspeciﬁed, n ¼ 1 [24]. Moreover, Foss et al. described
serious adverse events in 15 of 25 subjects treated with ECP,
namely pneumonia, n ¼ 5; cytomegalovirus colitis, n ¼ 1;
gastrointestinal bleeding, n¼ 1; urosepsis, n¼ 1; line-related
complications, n ¼ 2 (line sepsis, n ¼ 1; deep venous
thrombosis, n ¼ 1); and unspeciﬁed, n ¼ 5 [25].
ECP-Related Mortality
For acute GVHD, 4 studies (45 patients) [22,23,28,29] re-
ported data on incidence of ECP-related mortality. No deathswere reported as a result of ECP use. Moreover, 4 studies (75
patients) reported data on incidence of ECP-relatedmortality
for chronic GVHD [22-24,28]. One death on 1 study was
attributed to sepsis and idiopathic acute respiratory distress
syndrome, among other reasons [24]. The other 3 studies
reported no treatment-related deaths among patients with
chronic GVHD.
Discontinuation of Immunosuppressive Therapy
Acute GVHD
The pooled rate of discontinuation of immunosuppressive
therapies, including corticosteroids, from 3 studies (36 pa-
tients) was .55 (95% CI, .40 to .70) [23,28,29] (Figure 5A).
There was no heterogeneity between studies (I2 ¼ 0%). These
studies did not report the median time-to-discontinuation of
immunosuppressive therapies.
Chronic GVHD
Similarly, the pooled rate of discontinuation of immuno-
suppressive therapies, including corticosteroids, from 3
studies (54 patients) was .23 (95% CI, .07 to .44) [23,25,28]
(Figure 5B). The heterogeneity between studies was high
(I2 ¼ 68%). Again, these studies did not report the median
time-to-discontinuation of immunosuppressive therapies.
LIMITATIONS
We identiﬁed several limitations associated with this
analysis. For instance, although all included studies referred
to steroid-refractory or intolerant patients, the deﬁnition of
these terms varied across the studies (Appendix 3). More-
over, there was a lack of uniform criteria when deﬁning
overall responses. Four of the studies included in this anal-
ysis deﬁned overall response as 50% or greater response in at
Figure 5. Discontinuation of immunosuppressive therapy in acute (A) and chronic (B) GVHD.
I. Abu-Dalle et al. / Biol Blood Marrow Transplant 20 (2014) 1677e1686 1683least 1 site or organ involved [23,25,26,28]. Other studies
deﬁned response as the presence of at least 50% improve-
ment in clinical signs [29] or 50% or better improvement in
measurable parameters of GVHD, such as surface area
involved, liver enzyme values, volume of diarrhea, or
improvement in pulmonary function tests [22]. Moreover,
studies differed in regards to frequency, tapering schedule,
and length of the prescribed ECP therapy [22,24,26,27,29,40].
Additional sensitivity or subgroup analyses could not be
performed for assessment of heterogeneity because of the
small number of included studies. ECP can be performed
with 2 different methods, which differ in the context of
mononuclear cell collection and UVA irradiation. For
example, Therakos devices (West Chester, PA) provide
mononuclear cell collection with a discontinuous or contin-
uous ﬂow method and then UVA irradiation in a 1-step
method (or in-line procedure). On the other hand, COBE
devices (TERUMO BCT, Inc, Lakewood, CO) are used for
automated mononuclear cell collection, then UVA irradiation
is operated manually (off-line procedure or 2-step method).
There have been no head-to-head comparisons of ECP
methods, which pose a limitationwhen analyzing the data in
aggregate.
DISCUSSION
This represents the ﬁrst comprehensive systematic anal-
ysis of treatment outcomes of ECP in corticosteroid-
refractory acute or chronic GVHD in both pediatric and
adult populations. Through the comprehensive literature
search, we identiﬁed 9 studies, including 1 RCT, totaling over
300 subjects included in the analysis. We analyzed the out-
comes of ECP treatment for both beneﬁcial and harmful
endpoints in acute and chronic GVHD, and data were sum-
marized in pooled analyses. With the exception of 2 single-
arm studies [25,28], which included 52 subjects with
steroid-intolerant acute or chronic GVHD, the remaining 6
single-arm studies included 176 subjects only with steroid-
refractory or steroid-dependent acute or chronic GVHD
[22-24,26,27,29]. Unfortunately, it was not possible to
ascertain speciﬁc outcomes for subjects treated for steroid-
intolerant acute or chronic GVHD because of our inability
to determine the number of subjects treated for this partic-
ular indication or the corresponding post-ECP treatment
outcomes. We found that ORR for steroid-refractory/
dependent/intolerant acute GVHD in all organs approached
70%, pooling 6 different studies. This pooled ORR is quite
intriguing and appears favorable in comparison with otherpharmacologic interventions commonly utilized in the
setting of second-line systemic therapy for acute GVHD,
where no single treatment emerges as an accepted standard
of care [21].
Our analysis highlights varying organ-speciﬁc responses
in accordance with other studies, which provide insights on
most appropriate target organs for ECP therapy. With regard
to acute GVHD, ECP appears particularly useful in skin GVHD,
with a pooled ORR of .84 (95% CI, .75 to .92) followed by
gastrointestinal GVHD. A similar pattern of organ-speciﬁc
response was observed in chronic GVHD. Of note, ECP ther-
apy did not yield meaningful responses in chronic pulmo-
nary GVHD.
ECP was ﬁrst established as a promising therapy for
cutaneous T cell lymphoma [41], and the seminal work by
Edelson et al. led to the Food and Drug Administration’s
approval for this modality for this disease. ECP is an
apheresis-based therapy, where approximately 5  109
transplant-recipient leukocytes are treated with a photo-
activatable 8-methoxypsoralen, followed by exposure to
approximately 1.5 Joules/cm2 of UVA and reinfusion of
treated leukocytes to recipients in a closed-loop system [42].
ECP effectively induces cell death on most of the treated
leukocytes within 24 to 48 hours [43,44]. Infusion of EPC-
treated cells (ie, apoptotic cells) in this context appears to
be cleared by antigen presenting cells, which apparently
leads to immune modulation and immune tolerance induc-
tion [42]. There are several potential mechanisms of toler-
ance induction by apoptotic cells in GVHD, reviewed by Peritt
et al., including inhibition of proinﬂammatory cytokines,
increased production of anti-inﬂammatory cytokines, sup-
pressed effector T cell stimulation, elimination of effector
T cells, and induction of regulatory T cells [42]. Most recently,
the induction of monocyte to dendritic cell maturation in the
context of ECP was evaluated and the important role of
dendritic cells in the mechanism of ECP is being increasingly
recognized [33,45].
ECP is an effective nonpharmacologic modality for
patients with steroid-refractory GVHD with relatively low
risk of infections and other toxicities, as demonstrated in
this analysis. ECP can be combined with other pharmaco-
logic immunosuppression and a combination therapy may
also offer potential for better GVHD control. Taken together,
the Blood and Marrow Transplant Clinical Trial Network
originally designed a phase 2 randomized multicenter
study evaluating the role of ECP þ prednisone þ sirolimus
against the standard immunosuppressive therapy of
I. Abu-Dalle et al. / Biol Blood Marrow Transplant 20 (2014) 1677e16861684glucocorticoids þ calcineurin inhibitor for the upfront
treatment of chronic GVHD (protocol 0801). Unfortunately,
the ECP component of the trial was closed because of
slow accrual (http://www.clinicaltrials.gov/ct2/show/
NCT01106833). One important question remains unan-
swered in the transplantation community: whether the
place for ECP may be expanded to an upfront treatment
setting for GVHD. This will need to be addressed in future
multicenter clinical trials.
Therapeutic Recommendations
Based on our current systematic review of available
evidence on prospective studies, the following recom-
mendations regarding the use of ECP for patients with
steroid-refractory GVHD may be considered in line with
recommendations or guidelines set forth by professional
societies [21,46,47].
In adults as well as in children, ECP is an effective treat-
ment modality for corticosteroid-refractory acute GVHD. ECP
will likely be more beneﬁcial to those with skin involvement.
Treatment response for acute GVHD involving visceral or-
gans may be expected in over one half of patients. Of note,
ECP’s steroid-sparing effects would be desirable for these
immunosuppressed patients and potentially preserving the
putative graft-versus-tumor effect.
For chronic GVHD, ECP can be considered for steroid-
refractory disease in patients in both adult and pediatric
age groups. Organ-speciﬁc response appears to be higher in
cutaneous, gastrointestinal, hepatic, and oral mucosa.
Response in musculoskeletal chronic GVHD is expected to be
less than 50% (though the number of treated patients for this
particular indication is limited). Our analysis hints to a very
limited role of ECP on pulmonary chronic GVHD [48].
ECP is considered relatively safe with very limited toxic-
ities. Careful patient assessment for eligibility to ECP proce-
dure and close monitoring while on ECP therapy by
transfusion medicine and/or transplantation physicians are
still required. Particular attention is necessary considering
the rapidly changing clinical status of GVHD patients,
focusing on hemodynamic compromise and renal functions.
Hematologic parameters including anemia and thrombocy-
topenia ought to be optimized, with transfusion support
before initiation of therapy.
There is no consensus on the optimal ECP schedule. A
commonly used schedule may start with 3 times per week
and then decrease frequency to a twice-per-week schedule,
as tolerated. For responders, it may be continued twice per
week every 2 to 4weeks until maximum response. Following
the usual clinical practice, GVHD response should be
assessed weekly for acute GVHD and every 1 to 2 months for
chronic GVHD.
CONCLUSION
ECP is an effective therapeutic modality for
corticosteroid-refractory acute and chronic GVHD. It yields
varying organ-speciﬁc responses favoring cutaneous, fol-
lowed by gastrointestinal and hepatic. Favorable safety pro-
ﬁles of ECP allow its applicability to immunosuppressed
allograft recipients. ECP appears to facilitate reduction of
pharmacologic immunosuppression, including corticoste-
roids. Further research is needed to elucidate the precise
mechanism of ECP and to improve treatment outcomes.
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#2 “Photochemotherapy”[Mesh]
#3 “PUVA Therapy”[Mesh]
#4 Photophere*
#5 photochemo*
#6 puva therapy
#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6) ¼> treatment search
#8 “Graft vs Host Disease”[Mesh]
#9 Graft vs Host
#10 Graft versus Host
#11 Graft v Host
#12 GVHD
#13 runt diseas*
#14 homologous wasting diseas*
#15 (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14) ¼> disease
search
#16 (#7 AND #15) ¼> Final search strategy
#1 MeSH descriptor: [Photopheresis]
#2 MeSH descriptor: [Photochemotherapy]
#3 Photophere*
#4 photochemo*
#5 Puva therapy
#6 #1 OR #2 OR #3 OR #4 OR #5 ¼> treatment search
#7 MeSH descriptor: [Graft vs Host Disease]
#8 Graft vs Host
#9 Graft versus Host
#10 Graft v Host
#11 GVHD
#12 runt diseas*
#13 homologous wasting diseas*
#14 #8 OR #9 OR #10 OR #11 OR #12 OR #13 ¼> disease search
#15 #6 AND #14 ¼> Final search strategy
Study Random Sequence
Generation
Allocation
Concealment
Performance
Bias
Detection
Bias
Attrition Bias
Minimized
Reporting Bias
Minimized
Randomized Controlled Trials
Flowers, 2008 Yes Unclear Unclear Unclear Yes Yes
Study Representativeness
of Study Sample
Ascertainment
of Exposure
Demonstration Outcome
Was not Present at Start
Detection Bias
Minimized
Follow-up Time
Appropriate
Attrition Bias
Minimized
Noncomparative Studies
Smith, 1998 Yes Yes Yes Yes Unclear Yes
Salvaneschi, 2001 No Yes Yes Unclear Yes Yes
Seaton, 2003 Yes Yes Yes Unclear Yes Yes
Foss, 2005 No Yes Yes Unclear Yes Yes
Garban, 2005 Yes Yes Yes Unclear Unclear Yes
Greinix, 2006 No Yes Yes Unclear Yes Yes
Kanold, 2007 No Yes Yes Unclear Yes Yes
Calore, 2008 No Yes Yes Unclear Yes Yes
APPENDIX 2. METHODOLOGICAL QUALITY OF INCLUDED
STUDIES
Cochrane CENTRAL
Dates of search: From inception to 05 March 2013
MEDLINE via PubMed
Study Deﬁnition
Smith, 1998 Patients with GVHD who fail to respond to standard drug therapy with steroids, cyclosporine, monoclonal antibodies, and
antithymocyte globulin
Salvaneschi, 2001 Not deﬁned
Seaton, 2003 Patients refractory to conventional immunosuppressive treatment
Foss, 2005 Refractory disease after being treated with steroids, cyclosporine A, tacrolimus, and/or mycophenolate mofetil
Garban, 2005 Refractory to corticosteroids (2-3 mg/kg/day of prednisone for a minimum 5 days associated with either cyclosporine or
cyclosporine þ mycophenolate mofetil)
Greinix, 2006 Not deﬁned
Kanold, 2007 Absence of clinical and biologic improvement after at least 7 days of conventional treatment for acute GVHD or 2 months for
chronic GVHD; or severe acute or chronic GVHD responding to treatment but with intolerance, as assessed on a case-by-case
basis by a physician
Calore, 2008 Patients experiencing a ﬂare-up of acute GVHD during the tapering of methylprednisolone
Flowers, 2008 Lack of response or disease progression after at least 1 mg/kg of methylprednisolone equivalent
APPENDIX 3 DEFINITION OF STEROID-REFRACTORY
GRAFT-VERSUS-HOST DISEASE (GVHD) USED IN
INCLUDED STUDIES
